Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
September 2012
Features
The Nanomedicine Revolution
Part 1: Emerging Concepts
Nanoparticles may soon be used to transport diagnostic and therapeutic drugs to targeted sites not normally accessible, thereby improving treatment and reducing costs. Further research is still needed to establish the efficacy and safety of these nanomaterials.
C. Lee Ventola, MS
Role of Alvimopan (Entereg) in Gastrointestinal Recovery and Hospital Length of Stay After Bowel Resection
A retrospective chart review revealed that patients receiving alvimopan after bowel surgery had faster recovery times, better surgical care, and lower costs of care compared with patients who did not receive the drug.
Shan Wang, PharmD, RPh; Neal Shah, PharmD Candidate; Jessin Philip, PharmD, RPh; Tom Caraccio, PharmD; Martin Feuerman, MS; and Brian Malone, MS, RPh
Meeting Highlights
Second European Post-Chicago Melanoma Meeting 2012
Selected topics include targeted and chemotherapeutic agents (darafenib, trametinib), immunotherapies (ipilimumab, T-VEC, Rose Bengal), and the
continuing role of single-agent and combination chemotherapy.
Walter Alexander
Departments
Letters to the Editor
Makena or Compounded 17P?; Clarification on Hydrocodone (Zohydro)
Medication Errors
Safeguards for Using and Designing Automated Dispensing Cabinets
Automated dispensing cabinets have had a mixed record on improving drug safety.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Pharmacists Welcome FDA’s Opioids REMS
How Directly Will They Be Affected?
Pharmacists will need to become well versed in the FDA’s REMS for opioids.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Pharmaceutical Approval Update
Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2–positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD
Marvin M. Goldenberg, PhD, RPh, MS
Drug Forecast
Ipilimumab (Yervoy) Prolongs Survival In Advanced Melanoma
Serious Side Effects and a Hefty Price Tag May Limit Its Use
Chris Fellner
